Chlorpropamide
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Chlorpropamide: Drug Repurposing Evaluation Report
One-Sentence Summary
Chlorpropamide is a first-generation sulfonylurea historically used for the management of type 2 diabetes mellitus. The TxGNN model has not generated any predicted new indications for this drug, and the evidence pack contains no clinical trials or publications to support repurposing at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in evidence pack (known: Type 2 diabetes mellitus) |
| Predicted New Indication | None — no predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (No predictions or supporting studies) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, the TxGNN model has not generated any repurposing predictions for chlorpropamide. Without a predicted new indication, a mechanistic rationale cannot be evaluated.
From general pharmacological knowledge, chlorpropamide is a first-generation sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. However, detailed mechanism of action data was not available in this evidence pack (marked as a data gap). The drug has largely fallen out of clinical use globally due to its exceptionally long half-life (approximately 36 hours), which confers an elevated risk of prolonged and severe hypoglycaemia compared to newer sulfonylureas.
As there is no predicted indication to assess, and the drug currently holds no marketing authorisation in the United Kingdom, there is insufficient basis to pursue repurposing at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Chlorpropamide holds no current marketing authorisations in the United Kingdom. The drug has been discontinued from the UK market. No MHRA-authorised products are listed.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: The evidence pack contained no safety data (key warnings, contraindications, and drug interactions were all unavailable). Given that chlorpropamide is a first-generation sulfonylurea with a known risk profile — including prolonged hypoglycaemia, hyponatraemia (SIADH-like effect), and disulfiram-like reactions with alcohol — a thorough safety review from primary sources (BNF, SmPC) would be essential before any repurposing consideration.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model has not identified any repurposing candidates for chlorpropamide. Combined with the absence of UK marketing authorisations, the lack of mechanism of action data in the evidence pack, and the drug’s known unfavourable safety profile relative to modern alternatives, there is no basis to advance this candidate at present.
To proceed, the following would be needed:
- TxGNN model predictions identifying at least one plausible new indication
- Detailed mechanism of action data (MOA) from DrugBank or primary pharmacology sources
- Safety data including SmPC warnings, contraindications, and drug–drug interactions
- Assessment of whether a UK marketing authorisation holder or specials manufacturer could supply the product
- Clinical or preclinical evidence linking chlorpropamide to any novel therapeutic area
This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application. Report generated: 2026-04-05.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.